High-throughput Identification of Membrane Protein MAbs

描述（由申请人提供）：膜蛋白控制信息、营养物质和信号通过细胞膜的流动，并且是超过40%的fda批准药物的靶标。针对膜蛋白的单克隆抗体（mab）在研究、诊断和治疗应用中非常有用，但对于大多数膜蛋白，没有识别细胞表面天然蛋白的单克隆抗体。业界和NIH已经认识到对这种单克隆抗体的需求，但由于在外源系统中表达和纯化膜蛋白的困难以及传统的单克隆抗体分离策略通常一次只关注一个目标，因此鉴定这种单克隆抗体的努力受到限制。为了获得针对整个人膜蛋白质组的单克隆抗体，需要一种高通量的膜蛋白单克隆抗体鉴定新方法。在这里，我们提出了一种平台技术，可用于快速分离针对结构完整膜蛋白的单克隆抗体，用于治疗开发，诊断和生物医学研究。

DESCRIPTION (provided by applicant): Membrane proteins control the flow of information, nutrients, and signals through the cell membrane, and are the targets for more than 40% of FDA-approved drugs. Monoclonal antibodies (MAbs) that target membrane proteins can be exceptionally useful in research, diagnostic, and therapeutic applications, but for most membrane proteins there are no MAbs that recognize the native protein on the cell surface. The need for such MAbs has been recognized by industry and the NIH, but efforts to identify such MAbs are limited by the difficulty in expressing and purifying membrane proteins in exogenous systems and by conventional MAb isolation strategies that typically focus on one target at a time. A novel approach to identify membrane protein MAbs in a high-throughput manner is needed to derive MAbs against the entire human membrane proteome. Here we propose a platform technology that can be used to rapidly isolate MAbs against structurally-intact membrane proteins for therapeutic development, diagnostics, and biomedical research.